224 related articles for article (PubMed ID: 20578835)
1. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
3. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
4. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
5. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
[TBL] [Abstract][Full Text] [Related]
7. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
9. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
10. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
11. No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity.
Verberne HJ; de Bruin K; Habraken JB; Somsen GA; Eersels JL; Moet F; Booij J; van Eck-Smit BL
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):483-90. PubMed ID: 16425032
[TBL] [Abstract][Full Text] [Related]
12. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology.
Vallabhajosula S; Nikolopoulou A
Semin Nucl Med; 2011 Sep; 41(5):324-33. PubMed ID: 21803182
[TBL] [Abstract][Full Text] [Related]
13. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
[TBL] [Abstract][Full Text] [Related]
14. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
15. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
16. Efficient production of therapeutic doses of [131I]-metaiodobenzylguanidine for clinical use.
Prabhakar G; Mathur A; Shunmugam G; Teje YD; Sachdev SS; Sivaprasad N
Appl Radiat Isot; 2011 Jan; 69(1):63-7. PubMed ID: 20933432
[TBL] [Abstract][Full Text] [Related]
17. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
18. No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Appl Radiat Isot; 2005 Mar; 62(3):435-40. PubMed ID: 15607920
[TBL] [Abstract][Full Text] [Related]
19. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
[TBL] [Abstract][Full Text] [Related]
20. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
